Blog
RSS FeedPosted by Michael Wonder on 22 Aug 2019
ABPI position on US trade deal and medicines pricing
21 August 2019 - In response to concerns about the impact a US trade deal would have on medicine pricing, ...
Posted by Michael Wonder on 14 Aug 2019
Drug company Aspen may pay NHS £8 million after investigation alleges illegal deal to hike drug price
14 August 2019 - The drug company Aspen may have to pay the NHS £8 million (€8.7 million ; $9.7 ...
Posted by Michael Wonder on 12 Aug 2019
Drug maker 'will make $21 billion from treating cystic fibrosis'
12 August 2019 - Vertex is accused of raking in vast profits while making Orkambi unaffordable to NHS. ...
Posted by Michael Wonder on 12 Aug 2019
Is rate of return pricing a useful approach when value based pricing is not appropriate?
12 August 2019 - The pricing of new health technologies, such as drugs or devices, involves deciding how the economic ...
Posted by Michael Wonder on 28 May 2019
UK refuses to back 'game-changing' resolution on drug pricing
28 May 2019 - Global agreement urges governments to share information on actual cost of medicines, with aim of making them ...
Posted by Michael Wonder on 21 May 2019
The global battle over high drug prices
21 May 2019 - Western countries, as well as poor ones, are demanding transparency in the cost of drugs. ...
Posted by Michael Wonder on 13 May 2019
The UK’s new medicines pricing deal – opportunities and risks for pharma
10 May 2019 - January 2019 saw the introduction of the new Voluntary Scheme for Branded Medicines Pricing and Access ...
Posted by Michael Wonder on 01 May 2019
Drug maker Takeda to introduce value-based pricing in Europe
29 April 2019 - Japanese company to refund Crohn's disease patients with no improvements. ...
Posted by Michael Wonder on 01 Apr 2019
Assessing data sources for medicine price studies
29 March 2019 - There is no established methodology to assess the feasibility of medicine price data sources. ...
Posted by Michael Wonder on 18 Mar 2019
CMA drops anti-competitive case against MSD
18 March 2019 - The Competition and Markets Authority has closed its investigation into a suspected anti-competitive discount scheme developed ...
Posted by Michael Wonder on 12 Mar 2019
Optimism on Orkambi in England as talks to resume
12 March 2019 - Scotland's deal puts pressure on NHS England and NICE. ...
Posted by Michael Wonder on 08 Mar 2019
High price of cystic fibrosis drug not political, firm's boss tells MPs
8 March 2019 - CEO of company that makes Orkambi denies being ‘political minion’ for Donald Trump. ...
Posted by Michael Wonder on 05 Mar 2019
How to fix a problem like Orkambi? Solutions suggested ahead of showdown
5 March 2019 - Approaches used in France and Germany could help break deadlock. ...
Posted by Michael Wonder on 21 Feb 2019
Linking cancer drug prices to treatment success could speed up approvals. But what do patients consider success?
21 February 2019 - The NHS spends more than £2 billion on cancer drugs each year in the UK. And ...
Posted by Michael Wonder on 12 Feb 2019
Cystic fibrosis scandal: fury over US firm's 'refusal' to set price for life-saving drugs
11 February 2019 - A US drugs firm is "playing with people's lives" by refusing to do a deal over Orkambi, ...